Patents Assigned to Parker Hughes Institute
  • Patent number: 7186736
    Abstract: The present invention is directed to compounds and methods suitable for the treatment of HIV infection.
    Type: Grant
    Filed: March 20, 1999
    Date of Patent: March 6, 2007
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Publication number: 20070015733
    Abstract: Methods of inhibiting virus replication of in a cell infected with a resistant strain of HIV that includes administering to the infected cell a virus replication inhibiting amount of an aryl phosphate derivative of d4T.
    Type: Application
    Filed: May 30, 2006
    Publication date: January 18, 2007
    Applicant: Parker Hughes Institute
    Inventor: Fatih Uckun
  • Publication number: 20060293285
    Abstract: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or more substituents on the aryl group, and wherein the phosphorus of the aryl phosphate group is attached to an amino acid residue that may be esterified or substituted, such as a methoxyalaninyl group.
    Type: Application
    Filed: December 9, 2005
    Publication date: December 28, 2006
    Applicant: PARKER HUGHES INSTITUTE
    Inventor: Fatih Uckun
  • Publication number: 20060276491
    Abstract: The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.
    Type: Application
    Filed: November 17, 2003
    Publication date: December 7, 2006
    Applicant: Parker Hughes Institute
    Inventors: Fatih Uckun, Elise Sudbeck, Marina Cetkovic, Ravi Malaviya, Xing-Ping Liu
  • Patent number: 7144874
    Abstract: Methods of inhibiting virus replication of in a cell infected with a resistant strain of HIV that includes administering to the infected cell a virus replication inhibiting amount of an aryl phosphate derivative of d4T.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: December 5, 2006
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Publication number: 20060183729
    Abstract: Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.
    Type: Application
    Filed: August 12, 2005
    Publication date: August 17, 2006
    Applicant: Parker Hughes Institute
    Inventor: Fatih Uckun
  • Patent number: 7091351
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: August 15, 2006
    Assignee: Parker Hughes Institute
    Inventors: Yanhong Dong, Phalguni Gosh, Fatih M. Uckun
  • Publication number: 20060167090
    Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors, including allergy treatments.
    Type: Application
    Filed: June 21, 2004
    Publication date: July 27, 2006
    Applicant: Parker Hughes Institute
    Inventors: Fatih Uckun, Ravi Malaviya
  • Patent number: 7071176
    Abstract: Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. In a preferred aspect of the present invention, the phosphorus of the aryl phosphate group is further substituted with an amino acid residue that may be esterified or substituted, such as a methoxy alaninyl group.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: July 4, 2006
    Assignee: Parker Hughes Institute
    Inventors: Faith M. Uckun, Rakesh Vig
  • Patent number: 7064114
    Abstract: A pharmaceutical composition adapted for use as a spermicide, the composition comprising a gel-microemulsion comprising an oil-in-water microemulsion and a polymeric hydrogel. The gel-microemulsion can be used in a spermicidal method. Also, a gel-microemulsion pharmaceutical composition adapted for use as a formulation base for additional therapeutic agents. Examples of additional agents include, anti-microbial agents and spermicidal agents. Such gel-microemulsions with additional therapeutic agents can be used in methods for appropriate therapeutic treatment. Also, a gel-microemulsion pharmaceutical composition that is adapted for use as both a spermicide and formulation base for anti-microbial agents to provide a dual function contraceptive/anti-microbial formulation. Method of using such a composition as a dual function contraceptive/anti-microbial formulation are also included.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: June 20, 2006
    Assignee: Parker Hughes Institute
    Inventors: Seang Yiv, Mingshu Li, Osmond D'Cruz, Faith M. Uckun
  • Publication number: 20060106006
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Application
    Filed: January 5, 2006
    Publication date: May 18, 2006
    Applicant: Parker Hughes Institute
    Inventors: Fatih Uckun, Yanhong Dong, Phalguni Gosh
  • Patent number: 7037937
    Abstract: Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: May 2, 2006
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Shyi-Tai M. Jan
  • Patent number: 7038049
    Abstract: The present disclosure includes compounds, for example a compound according to formula I or a pharmaceutically acceptable salt thereof. The compounds of the present disclosure are useful in methods of treating cancerous conditions.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 2, 2006
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu, Rama Krishna Narla
  • Publication number: 20060046972
    Abstract: The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation associated with proliferative cell disorders in a subject by administering Compound 003 or metabolites thereof. The invention also provides methods for arresting the cell cycle. Methods of inhibiting proliferation of cells for treatment of cancer by administering Compound 003 are described.
    Type: Application
    Filed: August 31, 2005
    Publication date: March 2, 2006
    Applicant: Parker Hughes Institute
    Inventors: Fatih Uckun, Taracad Venkatachalam
  • Publication number: 20050277620
    Abstract: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or mote substituents on the aryl group selected from the group consisting of: 3-N(CH3)2; 2,6-(CH3O)2; 4Br-2-Cl; and 2,5-Cl2, and wherein the phosphorus of the aryl phosphate group is N-linked to an methyl or ethyl ester of an amino acid residue such as a methoxyalaninyl group.
    Type: Application
    Filed: May 12, 2003
    Publication date: December 15, 2005
    Applicant: Parker Hughes Institute
    Inventor: Fatih Uckun
  • Patent number: 6960606
    Abstract: Novel aromatic and heterocyclic thiazolyl thiourea compounds, pharameutical compositions including such, and methods for their use are disclosed. The compounds are effective agents for the treatment of HIV infection, including non-nucleoside inhibitor-resistant, and multi-drug resistant strains of HIV.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: November 1, 2005
    Assignee: Parker Hughes Institute
    Inventors: Faith M. Uckun, Taracad K. Venkatachalam
  • Patent number: 6958359
    Abstract: Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: October 25, 2005
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Patent number: 6953875
    Abstract: A transgenic zebrafish animal model is disclosed. The model can be used for study of hematopoetic cell differentiation, control, and screening of therapeutic agents and can include a transgenic zebrafish expressing a heterologous Ikaros protein.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: October 11, 2005
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Alexcy O. Benyumov
  • Publication number: 20050196851
    Abstract: The invention provides crystal structure of the kinase domain of BTK, as well as use of the crystal structure in the design, identification, and verification of ligands that modulate BTK activity.
    Type: Application
    Filed: February 13, 2004
    Publication date: September 8, 2005
    Applicant: Parker Hughes Institute
    Inventor: Fatih Uckun
  • Publication number: 20050198696
    Abstract: A transgenic zebrafish animal model for the study of haemopoietic cell differentiation, control, and screening of therapeutic agents.
    Type: Application
    Filed: March 23, 2005
    Publication date: September 8, 2005
    Applicant: Parker Hughes Institute
    Inventors: Fatih Uckun, Alexey Benyumov